PCSK9 and cancer: Novel lipid-lowering drugs, such as PCSK9 inhibitors, could be proposed, as Quagliariello [35] did, putting forward the argument that PCSK9 inhibition in patients with cancer treated with ICI therapies enables a reduction in atherosclerotic cardiovascular events and potentially improves ICs-related anticancer functions.